Kornimate/medical-research-clean huggingface dataset:
the role of ctdna, pvt1 and ros in diagnosis and treatment of gastrointestinal and hepatobiliary pancreatic cancer

Conditions: Neoplasms, Gastrointestinal

Summary: this study aims to evaluate the role of ct-dna, pvt1 and reactive oxygen species (ros) as biomarkers in the diagnosis, treatment and recurrence monitoring of gastrointestinal and hepatobiliary pancreatic cancer.

epidemiological surveys showed a significant increasing trend of gastrointestinal and hepatobiliary pancreatic cancer in recent years. how can make an early diagnosis of gastrointestinal and liver cancer as well as prognostic evaluation and efficacy monitoring, has become the hotspot. "liquid biopsy", which is meant to detect cancers by sequencing the dna in a few drops of a person's blood. it may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation. ct-dna in cancer patients often bears similar genetic and epigenetic features to the related tumor dna. there is evidence that some of the ct-dna originates from tumoral tissue. besides, ct-dna can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer. it is known that levels of cellular ros correlate with the aggressiveness of tumour cells and prognosis of patients. cancer cells with increased endogenous ros stress are more sensitive to anticancer agents and high levels of ros generated by chemotherapeutic agents can induce cell death. hence, ros levels before and after chemotherapy in cancer cells can be an early indicator of treatment efficacy, which has the potential to shed new light on the choice of cancer therapy. this study aims to evaluate the role of ct-dna and ros as biomarkers in the diagnosis, treatment and recurrence monitoring of gastrointestinal and hepatobiliary pancreatic cancer.

Eligibility criteria:
inclusion criteria: * patients with suspected of gastrointestinal and hepatobiliary pancreatic cancer * age from 18 - 80 years * no serious organic and mental illness; exclusion criteria: * pregnancy * no pathologic result * suffering other malignancies at the same time.

Keywords: ctdna gastrointestinal cancer ros hepatobiliary pancreatic cancer
self-administered questionnaire to evaluate salt and potassium diet of patients followed in nephrology

Conditions: Nephropathy, Chronic Tubulointerstitial

Summary: the aim of the study is to create a self-questionnaire to evaluate sodium and potassium diet in chronic kidney disease patients. questionnaires will be compared to 24h sodium and potassium urinary excretion (reference) a bayesian network and a multiple regression will be used to select the most relevant items


Eligibility criteria:
inclusion criteria: * adult consulting in nephrology and having a 24h sodium urinary excretion routinely determined * consent informed agreement exclusion criteria: * do not want to participate
microbiotic analysis in digestive endocrine tumors

Conditions: Digestive Neuroendocrine Tumor; Fecal Microbiota; Bacterial Signature

Summary: incidence of digestive neuroendocrine tumors are increasing. analysis of individual microbiota is a way to explore new neoplastic mechanisms, tumor identification and therapeutic orientations. this prospective pilot study aims to describe fecal bacterial phylogeny of patients with digestive neuroendocrine tumor. bacterial genomic signature will be recorded at initiation of lanreotide treatment in naive patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or locally advanced, as well as after one year follow up.


Eligibility criteria:
inclusion criteria: * 18 years old or older * naive patient with digestive neuroendocrine tumor (pancreas (cytology or histology per endoscopy or on surgical specimen) or small intestine), secreting or not, initiating a extended release lanreotide treatment * registered with a social security scheme exclusion criteria: * medical contraindication to somatostatine analogs use * history of extended release somatostatine analogs treatment * antibiotic use or colonoscopic purge in the last 3 weeks preceding fecal sample * pregnant or breastfeeding women * person requiring tutorship, guardianship, or person legally protected
paracetamol metabolism in post operative conditions

Conditions: Aortic Surgery and Treatment Post Operative With Paracetamol During 4 Days

Summary: follow-up of urinary concentration from paracetamol metabolites by patients with aortic surgery during 4 days therapeutic intake (perfalgan ® 4 x 1g iv/day)

d-15 to d0: selection * patient information and non-opposition obtained * inclusion and non inclusion criteria check * clinical exam d-1 to d0 : 24 hours diuresis d0 : operation day before anesthesia : * urine collection (paracetamol metabolites dosage) * blood sampling (glutathion and liver function test) surgery: * 1st paracetamol intake before closing * then administration every 6 hours d1 to d4 : * 24 hours urine collection (metabolites dosage) * blood sampling et d1 and d4(glutathion and liver function test) d5 : final clinical exam

Eligibility criteria:
inclusion criteria: * aortic surgery * treatment with intraveinous paracetamol (4 grammes daily during 4 days) * patient agrees to participate exclusion criteria: * - patient disagrees * paracetamol contra-indication * paracetamol intake 5 days before surgery

Keywords: post operative conditions, paracetamol metabolites
electrical stimulation for the treatment of back pain using peripheral nerve stimulation (pns)

Conditions: Back Pain; Low Back Pain

Summary: the purpose of this study is to evaluate the effectiveness of electrical stimulation (low levels of electricity) on low back pain. this study involves the sprint peripheral nerve stimulation (pns) system. the system delivers mild electrical stimulation to the nerves in the low back. the system includes up to four small wires (called "leads") that are placed through the skin into the muscles in the low back. the wires attach to device(s) worn on the body that deliver stimulation (called stimulators).


Eligibility criteria:
key inclusion criteria: * at least 21 years of age * chronic low back pain key exclusion criteria: * infection on or around the low back * conditions with increased risk of infection (e.g., valvular heart disease, compromised immune system, history of recurrent skin infections) * implanted electronic device * body mass index (bmi) \> 40 * pregnant

Keywords: electrical stimulation neurostimulation neuromodulation back pain low back pain
pharmacodynamic of ceftaroline and levofloxacin against pathogens associated with community acquired bacterial pneumonia

Conditions: Pneumonia, Bacterial; Community-acquired

Summary: this study will further analyze the use of ceftaroline for cabp and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. the enhanced spectrum of ceftaroline compared to levofloxacin may be further highlighted from this investigation.


Eligibility criteria:
inclusion criteria: * non-pregnant adults (≥ 18 years old) with suspected cabp admitted to the hospital for parenteral antibiotic therapy. * all patients will have a creatinine clearance (crcl) \>50 ml/min. exclusion criteria: * pregnant or nursing patients, * allergy to penicillin/cephalosporin antibiotics, * allergy to fluoroquinolones, * renal or hepatic failure, or have received an antimicrobial in past 96h. * patients who require antibiotics other than the study drugs will also be excluded.

Keywords: pneumonia ceftaroline community-aquired
influence of tms on attention modulation

Conditions: Drinking, Alcohol

Summary: the purpose of this study is to help understand how attention processes influence brain engagement during emotion and social cognition. the investigators also want to know if these processes are associated with drinking alcohol. participation includes three study visits of about 2 hours each over approximately a month. the first visit involves a magnetic resonance imaging (mri) scan and answering survey questions. each of the next two visits will involve a session of transcranial magnetic stimulation (tms, a non-invasive brain stimulation technique) followed by another mri scan. people in the auburn/opelika area 19 or older are eligible to participate. people who drink alcohol and people who do not drink or don't drink very much are invited to participate.


Eligibility criteria:
inclusion criteria: 1. age 18 or older 2a. (drinker group): reports consuming 4 \[if female\]/ 5 \[if male\] or more standard drinks on one occasion at least 2 times a month and/or reports consuming more than 7 \[if female\]/ 14 \[if male\] standard drinks per week on average 2b. (healthy volunteer group): reports consuming 4 \[if female\]/ 5 \[if male\] or more standard drinks on one occasion less than once a month and reports consuming less than 7 \[if female\]/ 14 \[if male\] standard drinks per week on average exclusion criteria: 1. mri contraindications 1. presence of metal in the body that would make having a 7t mri unsafe (including facial tattoos) 2. claustrophobia, such that individual would be unable to stay in the mri for up to 1 hr 3. hearing loss, including tinnitus, that might be made worse by mri or tms 2. tms contraindications 1. has ever had a seizure, or has a family history of epilepsy 2. taking medications or substances that lower the seizure threshold\* 3. implanted devices that are in the head or rely on physiological signals 4. history of neurological disease, such as stroke or brain tumor 5. head injury with loss of consciousness greater than 30 minutes 6. actively withdrawing from alcohol 3. family history of schizophrenia or presence of psychotic symptoms

Keywords: alcohol attention tms binge drinking emotion social cognition moral mri frontal eye fields moral cognition
fatigue in sjögren's syndrome: 3 therapeutic strategies

Conditions: Sjogren Syndrome

Summary: unexplained fatigue is a frequent (60-70%) chronic complaint in sjögren's syndrome (sjs) with a clear unmet therapeutic need, despite the recommendation of adapted physical activity (apa) programs, which are effective and feasible, but only to some extent. hence, other therapeutic approaches, such as acupuncture (acu) or transcutaneous vagal nerve stimulation (tvns), have been evaluated during the past years, with varying degrees of success in alleviating fatigue. fessona has been designed as a randomized controlled monocentric trial, aiming at comparing the effects of 3 different programs on fatigue in sjs: apa alone, apa+acu and apa+tvns. relevant controls will be included as well (sham acu and simulated tvns). multiple fatigue and sjs-related features will be measured before (at inclusion) and after (week 12) the intervention, as well as at week 24 and 48, to evaluate the short- and long-term impact of each program. tolerance and feasibility will also be evaluated.


Eligibility criteria:
inclusion criteria: * patient affiliated or entitled to a social security scheme. * age \> 18 years. * patient informed and having signed the information form and consent to participate in the study. * patient with sjögren's syndrome according to acr/eular 2016 or aecg 2002 criteria, usually followed up every year or more frequently * fatigue present for ≥ 6 months, without obvious explanation and/or specific treatment to conduct (e.g., disease's flare, chronic infection), with a current facit-f score \< 34 exclusion criteria: * pre-existing atrial fibrillation or severe cardiac conduction disorders, * recent stroke or myocardial infarction (\<6 months), * left ventricular ejection fraction \<40% or severe heart failure (new york heart association functional class iii or iv) * recurrent episodes of vasovagal syncope, or history of vagotomy * people with dermatological problems in the area where the stimulation electrodes are to be placed * current episode of venous or arterial thrombosis * pregnancy or breastfeeding * patient under protective measures (legal protection, curatorship, guardianship) * inability or refusal to understand and/or sign informed consent to participate in the study, or to perform follow-up examinations required under the study

Keywords: sjögren's syndrome fatigue acupuncture adapted physical activity (apa) transcutaneous vagal nerve stimulation (tvns)
bioequivalency study of anastrozole 1 mg under fasted conditions

Conditions: Breast Cancer

Summary: the objective of this study was to prove the bioequivalence of anastrozole tablet under fasted conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to anastrozole or any comparable or similar product.
a study of bpi-460372 in advanced solid tumor patients

Conditions: Advanced Solid Tumor

Summary: this study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of bpi-460372 in solid tumor patients.


Eligibility criteria:
inclusion criteria: * signed informed consent; * age ≥18, male and female patients； * expected survival ≥ 3 months； * eastern cooperative oncology group (ecog) performance status (ps) 0-1; * dose escalation phase: histologically or cytologically confirmed locally advanced or metastatic solid tumor patients, who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists; * dose expansion phase: histologically or cytologically confirmed locally advanced malignant mesothelioma, epithelioid hemangioendothelioma or other diagnosed solid tumor patients with nf2 defects, yap/taz fusion, lats1/2 mutations, and other hippo signaling pathway abnormalities , who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists; * evaluable lesion required for dose escalation phase and at least 1 measurable lesion as per recist v1.1 or mrecist v1.1 required for dose expansion phase; exclusion criteria: * patients who have previously received a tead inhibitor; * inadequate wash-out of prior therapies described per protocol, which may include anti-tumor therapies, tumor adjuvant drugs, organ or stem cell transplantation，etc； * patients with severe or unstable systemic disease, unstable/symptomatic cns metastasis, meningeal metastasis and spinal cord compression，malignant tumors, cardiac disease, bleeding or embolic disease, infectious disease, conditions affecting drug swallow and absorption, medical history leading to chronic diarrhea, etc; * pregnancy or lactation; * other conditions considered not appropriate to participate in this trial by the investigators.
sex steroids balance for metabolic and reproductive health in klinefelter syndrome

Conditions: Klinefelter Syndrome

Summary: the study seeks primarily to determine whether modulation of systemic and testicular sex steroids balance by aromatase inhibitors will positively affect the metabolic health and spermatogenesis of men with klinefelter syndrome (kfs) as compared to the current state of the art for each issue. secondary objectives of this study are (i) to unravel the heterogeneity of the reproductive and metabolic phenotype of men with kfs by performing a multi-omic analysis in a large cohort at baseline; (ii) to evaluate the efficacy of semaglutide-induced weight loss to achieve metabolic and reproductive benefit in men with klinefelter syndrome as compared to standard testosterone replacement; (ii) to assess whether addition of hcg to aromatase inhibitors further increases intratesticular testosterone and promotes spermatogenesis in men with kfs.


Eligibility criteria:
inclusion criteria: -diagnosis of klinefelter syndrome (47,xxy or mosaicism) design 1: * age range: 16-40 years old * intention to become parent or interest in fertility preservation * confirmed azoospermia (lack of spermatozoids) after centrifugation of one semen sample design 2: * age range: 18-65 years old * no interest in fertility or fertility preservation * hypogonadism at diagnosis or after wash-out of testosterone replacement therapy * high metabolic risk defined as overweight (bmi 25-28 kg/m2) and insulin resistance (homa-ir \> 2.6) exclusion criteria: * contraindications to testosterone-rising therapies (prostate or breast cancer, psa \> 4 µg/l, active liver disease, symptomatic heart disease) * decreased life expectancy due to terminal disease * known or suspected non-compliance, drug or alcohol abuse * inability to follow the procedures of the study (language problems, severe psychological or mental disorders)

Keywords: metabolic syndrome infertility aromatase testosterone/estradiol ratio mtese biopsy glp1 agonists
efficacy study of botox to treat neuropathic pain

Conditions: Postherpetic Neuralgia; Nerve Trauma

Summary: objectives : to investigate the analgesic effects and safety of intradermal botulinum toxin a injection in the treatment of focal painful neuropathies (eg, postherpetic neuralgia, nerve trauma)

the study will be randomized, performed in parallel group and double blind versus saline and will include 30 patients. botulinum toxin injection will be injected intradermally in the painful area (one single injection) following a method adapted from that used in hyperhidrosis. the patients will be followed for 6 months after the injection. primary outcome will be self-reported pain from the patients diaries. secondary outcomes will be neuropathic symptoms, quality of life, allodynia to brush and pressure, detection and pain thresholds, proportion of responders, pain relief and clinical global impression. clinical assessment will take place before injection then at 1 month, 3 months and 6 months.

Eligibility criteria:
inclusion criteria: * daily pain for at least 6 months of at least moderate intensity clearly attributed to the nerve lesion * limited area of pain * mechanical allodynia in the painful area exclusion criteria: * contraindication to btxa formulation * coagulation disorders * another painful condition * current major depression * history of drug or alcohol abuse * compensation claim or litigation * facial neuropathic pain
unilateral vs bilateral laparoscopic ovarian drilling in clomiphene citrate resistant cases of polycystic ovarian syndrome

Conditions: Laparoscopic; Ovarian Drilling; Clomiphene Citrate; Polycystic Ovarian Syndrome; Unilateral; Bilateral

Summary: the aim of the current study is to compare the efficacy of laparoscopic unilateral ovarian drilling with bilateral ovarian drilling in clomiphene citrate resistant cases of polycystic ovarian syndrome in terms of clinical response (regularity of the cycle), change in biochemical parameters, ovulation rate over six months, pregnancy rate within six months.

polycystic ovary syndrome (pcos), is considered the most common endocrine disorder in reproductive age in females. polycystic ovary syndrome (pcos) is characterized by reproductive and metabolic disturbances. androgen excess is a hallmark of polycystic ovary syndrome (pcos), driving many of the phenotypic features the clinical response to laparoscopic ovarian drilling (lod) seems to be thermal energy dose-dependent. two punctures (300 j) per ovary are associated with poor results. between three and five (450-750 j) punctures per ovary seem to represent the effective thermal dose. the application of six or more (c900 j) punctures per ovary may result in excessive destruction to the ovary and should therefore be discouraged.

Eligibility criteria:
inclusion criteria: * age within 25-35 years. * polycystic ovarian syndrome as diagnosed according to modified rotterdam criteria 2018: oligomenorrhea or amenorrhea; clinical and/or biochemical signs of hyperandrogenism; and transvaginal sonographic appearance of polycystic ovaries (≥ 20 follicles or an ovarian volume 10 cm3) . * infertile women who have clomiphene citrate -resistant polycystic ovary syndrome (150 mg/daily for 5 days for six cycles with no ovulation). * normal semen analysis in the husband. exclusion criteria: * hyper-androgenic disorders like late onset congenital adrenal hyperplasia, hyperprolactinemia, thyroid diseases. * cushing's syndrome and androgen-secreting tumors. * body mass index \> 30 kg/m2. * other medical problems like diabetes, hypertesion, patients on steroid hormone .... etc. * other causes of infertility as multiple uterine fibroids.
impact of massage therapy on the quality of life of hospice patients

Conditions: Pain; Anxiety; Depression; Quality of Life

Summary: this is a pilot study to evaluate the impact of massage therapy in hospice patients.

as an integrative therapy, there is growing evidence that massage therapy can be an effective therapeutic tool for relief of pain and non-pain symptoms in hospice and palliative care patients. massage therapy can provide comfort, relaxation, and improve quality of life for patients. the primary aim of the study is to gather data on the effects of complementary massage therapy on patient's symptoms and quality of life. the study goal is to improve patient symptoms of pain, anxiety, depression, and quality of life through the use of massage therapy provided to hospice patients. questionnaires would be utilized before and after each massage intervention and would quantify symptom and quality of life levels.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. clinically determined by hospice staff to be appropriate for massage therapy (esas-r scores of 5 or greater on pain, depression, anxiety, or best well-being) 3. place of residence within 30 minutes of downtown rochester 4. patient or caregiver must be able to participate in brief interviews and complete questionnaires (verbally or physically) exclusion criteria: 1. patients ineligible for massage therapy due to complexity of medical care including complex wound and multiple drains

Keywords: massage therapy hospice integrative medicine palliative care caregivers
observational cohort study evaluating the effectiveness of an education program (ngaydautien) in combination with gliclazide mr in the management of uncontrolled type 2 diabetic patients.

Conditions: Type 2 Diabetes

Summary: the primary objective is to assess the change of hba1c level from baseline after a 6-month follow up among uncontrolled patients with t2d who will be initiated to diamicron® mr 60 (originator product) plus an educational program (ngaydautien) as monotherapy or in add on to metformin in comparison to an initiation of an oral antidiabetic drug (oad) (except diamicron®) as monotherapy or in add on to metformin.


Eligibility criteria:
inclusion criteria: 1. aged at least 18 years (without upper limit of age) 2. hba1c value is required at the baseline visit 3. patients with diagnosis of uncontrolled t2d 4. initiation of a new oad as monotherapy or on top of metformin 5. patient follow-up within the scope of the current medical practice and in the same health center during the 6-month period. exclusion criteria: 1. diagnosis of diabetes other than t2d 2. hba1c value not available at baseline 3. patients who previously attended to the ndt educational program for t2d management 4. required at baseline an insulin therapy according to national guideline 5. used any other oad (except metformin) 6. used a single pill combination in addition to the medicine of interest 7. have a severe disease (i.e. cirrhosis, end stage renal disease...) 8. are unlikely to cooperate in the study or to follow the educational program

Keywords: observational hba1c type 2 diabetes diamicron® mr 60 t2d patient educational program